SREBF1 and metabolic syndrome: The increases in osteopontin, MCP-1, COX-2, IL-12, IL-1β and SREBP-1c mRNA levels in subcutaneous adipose tissue of the MetS group were prevented by HK L-137 at either dose (Fig. 6G–K and N).